<DOC>
	<DOC>NCT01395485</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics in adolescent and adult subjects with intermittent or mild to moderate persistent asthma.</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male and/or female subjects 12 to &lt; 18 years of age at the time of randomization Male and/or female subjects between 18 and 50 years of age (inclusive) at the time of randomization Body weight â‰¥ 36 kg at screening Intermittent or mild to moderate persistent asthma for at least the past 3 months prior to study enrollment (as defined by the 2004 Global Initiative for Asthma [GINA] guidelines. Experienced an asthma exacerbation (defined as a disease episode resulting in treatment in an emergency room or urgent care facility, or an episode treated with oral corticosteroids) during the 3 months prior to study enrollment. Hospitalized for asthma during the 6 months prior to study enrollment; or ever intubated for the treatment of asthma. Use of oral corticosteroids within 3 months prior to study enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Single Dose</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>